Podcast

Cargando

Guias/ Recomendaciones AAOC

Telemedicina

Atención Administrativa

Revista Digital

AAOC TV

oncoargentina.tv

registro de cancer y covid

Registros de Ensayos clínicos .org

esmo

Red Iberoamericana

cancer.net

MEDLINE Complete

LABx – Pfizer

Selnet

Medbinars

Publicaciones/revistas

Referencias:

  1. Torres-Guzman R et al. Oncotarget. 2017;8:69493-69507
  2. Kim S et al. Oncotarget. 2018;9:35226-35240
  3. Finn RS et al. Clin Cancer Res. 2020;26:110-121
  4. Delach S. SABCS 2020. Poster PS19-10
  5. Cejalvo JM et al., Cancer Res 77:2213-2221, 2017
  6. Prat A, et al., JAMA Oncol 2:1287-1294, 2016
  7. Turner et al.,  . J Clin Oncol 37:1169-1178, 2019
  8. Finn RS et al., Clin Cancer Res 26:110-121, 2019
  9. Finn R et al., Cancer Res 78, 2018 (abstr P2-P09-10-P2-09-10)
  10. Prat A. et al., Cancer Res Treat 135:301-306, 201.
  11. Turner et al.,. J Clin Oncol 37:1169-1178, 2019
  12. Prat A et al., J Clin Oncol. 2021 May 1;39(13):1458-1467
  13. Martínez-Sáez O. ESMO Breast 2021. Poster 23P
  14. Levin Tykjær Jørgensen C. Cancers. 2021;13:1592
  15. Braso-Maristany F. ESMO Breast 2021. Poster 16P.

AG2108048392

Referencias:

Harbeck et al., De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results. J Clin Oncol 39, 2021 (suppl 15; abstr 503)

Mayer et al., A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131.  J Clin Oncol 39, 2021 (suppl 15; abstr 605).

Tutt et al., OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.  J Clin Oncol 39, 2021 (suppl 15; abstr LBA1).

Slamon et al., Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). J Clin Oncol 39, 2021 (suppl 15; abstr 1001).

Cristofanilli et al., Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3. J Clin Oncol 39, 2021 (suppl 15; abstr 1000).

Kalinsky et al.,Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 39, 2021 (suppl 15; abstr 1011).

AG2107150104